Report Detail
Global Duchenne Muscular Dystrophy Drugs Market Research Report 2019
- RnM3108029 |
- 12 March, 2019 |
- Global |
- 119 Pages |
- QYResearch |
- Pharma & Healthcare
Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death.
The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.
The global Duchenne Muscular Dystrophy Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Duchenne Muscular Dystrophy Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Duchenne Muscular Dystrophy Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Akashi Therapeutics Inc
Antisense Therapeutics Ltd
Beech Tree Labs Inc
Biogen Inc
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SAS
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
CRISPR Therapeutics
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
FibroGen Inc
Fulcrum Therapeutics Inc
Galapagos NV
Genethon SA
GTx Inc
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
SOM Biotech SL
Strykagen Corp
Summit Therapeutics Plc
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
WAVE Life Sciences Ltd
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Development & Drug Target
Mechanism of Action (MoA)
Route of Administration (RoA)
Molecule Type
Segment by Application
Hospitals and Clinics
Medical Laboratories
Others
Table of Contents
Executive Summary
1 Duchenne Muscular Dystrophy Drugs Market Overview
- 1.1 Product Overview and Scope of Duchenne Muscular Dystrophy Drugs
- 1.2 Duchenne Muscular Dystrophy Drugs Segment by Type
- 1.2.1 Global Duchenne Muscular Dystrophy Drugs Production Growth Rate Comparison by Type (2014-2025)
- 1.2.2 Development & Drug Target
- 1.2.3 Mechanism of Action (MoA)
- 1.2.4 Route of Administration (RoA)
- 1.2.5 Molecule Type
- 1.3 Duchenne Muscular Dystrophy Drugs Segment by Application
- 1.3.1 Duchenne Muscular Dystrophy Drugs Consumption Comparison by Application (2014-2025)
- 1.3.2 Hospitals and Clinics
- 1.3.3 Medical Laboratories
- 1.3.4 Others
- 1.4 Global Duchenne Muscular Dystrophy Drugs Market by Region
- 1.4.1 Global Duchenne Muscular Dystrophy Drugs Market Size Region
- 1.4.2 North America Status and Prospect (2014-2025)
- 1.4.3 Europe Status and Prospect (2014-2025)
- 1.4.4 China Status and Prospect (2014-2025)
- 1.4.5 Japan Status and Prospect (2014-2025)
- 1.5 Global Duchenne Muscular Dystrophy Drugs Market Size
- 1.5.1 Global Duchenne Muscular Dystrophy Drugs Revenue (2014-2025)
- 1.5.2 Global Duchenne Muscular Dystrophy Drugs Production (2014-2025)
2 Global Duchenne Muscular Dystrophy Drugs Market Competition by Manufacturers
- 2.1 Global Duchenne Muscular Dystrophy Drugs Production Market Share by Manufacturers (2014-2019)
- 2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2014-2019)
- 2.3 Global Duchenne Muscular Dystrophy Drugs Average Price by Manufacturers (2014-2019)
- 2.4 Manufacturers Duchenne Muscular Dystrophy Drugs Production Sites, Area Served, Product Types
- 2.5 Duchenne Muscular Dystrophy Drugs Market Competitive Situation and Trends
- 2.5.1 Duchenne Muscular Dystrophy Drugs Market Concentration Rate
- 2.5.2 Duchenne Muscular Dystrophy Drugs Market Share of Top 3 and Top 5 Manufacturers
- 2.5.3 Mergers & Acquisitions, Expansion
3 Global Duchenne Muscular Dystrophy Drugs Production Market Share by Regions
- 3.1 Global Duchenne Muscular Dystrophy Drugs Production Market Share by Regions
- 3.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Regions (2014-2019)
- 3.3 Global Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.4 North America Duchenne Muscular Dystrophy Drugs Production
- 3.4.1 North America Duchenne Muscular Dystrophy Drugs Production Growth Rate (2014-2019)
- 3.4.2 North America Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.5 Europe Duchenne Muscular Dystrophy Drugs Production
- 3.5.1 Europe Duchenne Muscular Dystrophy Drugs Production Growth Rate (2014-2019)
- 3.5.2 Europe Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.6 China Duchenne Muscular Dystrophy Drugs Production (2014-2019)
- 3.6.1 China Duchenne Muscular Dystrophy Drugs Production Growth Rate (2014-2019)
- 3.6.2 China Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.7 Japan Duchenne Muscular Dystrophy Drugs Production (2014-2019)
- 3.7.1 Japan Duchenne Muscular Dystrophy Drugs Production Growth Rate (2014-2019)
- 3.7.2 Japan Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
4 Global Duchenne Muscular Dystrophy Drugs Consumption by Regions
- 4.1 Global Duchenne Muscular Dystrophy Drugs Consumption by Regions
- 4.2 North America Duchenne Muscular Dystrophy Drugs Consumption (2014-2019)
- 4.3 Europe Duchenne Muscular Dystrophy Drugs Consumption (2014-2019)
- 4.4 China Duchenne Muscular Dystrophy Drugs Consumption (2014-2019)
- 4.5 Japan Duchenne Muscular Dystrophy Drugs Consumption (2014-2019)
5 Global Duchenne Muscular Dystrophy Drugs Production, Revenue, Price Trend by Type
- 5.1 Global Duchenne Muscular Dystrophy Drugs Production Market Share by Type (2014-2019)
- 5.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2014-2019)
- 5.3 Global Duchenne Muscular Dystrophy Drugs Price by Type (2014-2019)
- 5.4 Global Duchenne Muscular Dystrophy Drugs Production Growth by Type (2014-2019)
6 Global Duchenne Muscular Dystrophy Drugs Market Analysis by Applications
- 6.1 Global Duchenne Muscular Dystrophy Drugs Consumption Market Share by Application (2014-2019)
- 6.2 Global Duchenne Muscular Dystrophy Drugs Consumption Growth Rate by Application (2014-2019)
7 Company Profiles and Key Figures in Duchenne Muscular Dystrophy Drugs Business
- 7.1 Akashi Therapeutics Inc
- 7.1.1 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 7.1.2 Duchenne Muscular Dystrophy Drugs Product Introduction, Application and Specification
- 7.1.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.1.4 Main Business and Markets Served
- 7.2 Antisense Therapeutics Ltd
- 7.2.1 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 7.2.2 Duchenne Muscular Dystrophy Drugs Product Introduction, Application and Specification
- 7.2.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.2.4 Main Business and Markets Served
- 7.3 Beech Tree Labs Inc
- 7.3.1 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 7.3.2 Duchenne Muscular Dystrophy Drugs Product Introduction, Application and Specification
- 7.3.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.3.4 Main Business and Markets Served
- 7.4 Biogen Inc
- 7.4.1 Biogen Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 7.4.2 Duchenne Muscular Dystrophy Drugs Product Introduction, Application and Specification
- 7.4.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.4.4 Main Business and Markets Served
- 7.5 Bioleaders Corp
- 7.5.1 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 7.5.2 Duchenne Muscular Dystrophy Drugs Product Introduction, Application and Specification
- 7.5.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.5.4 Main Business and Markets Served
- 7.6 BioMarin Pharmaceutical Inc
- 7.6.1 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 7.6.2 Duchenne Muscular Dystrophy Drugs Product Introduction, Application and Specification
- 7.6.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.6.4 Main Business and Markets Served
- 7.7 Biophytis SAS
- 7.7.1 Biophytis SAS Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 7.7.2 Duchenne Muscular Dystrophy Drugs Product Introduction, Application and Specification
- 7.7.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.7.4 Main Business and Markets Served
- 7.8 Capricor Therapeutics Inc
- 7.8.1 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 7.8.2 Duchenne Muscular Dystrophy Drugs Product Introduction, Application and Specification
- 7.8.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.8.4 Main Business and Markets Served
- 7.9 Catabasis Pharmaceuticals Inc
- 7.9.1 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 7.9.2 Duchenne Muscular Dystrophy Drugs Product Introduction, Application and Specification
- 7.9.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.9.4 Main Business and Markets Served
- 7.10 CRISPR Therapeutics
- 7.10.1 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 7.10.2 Duchenne Muscular Dystrophy Drugs Product Introduction, Application and Specification
- 7.10.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.10.4 Main Business and Markets Served
- 7.11 Cumberland Pharmaceuticals Inc
- 7.12 Daiichi Sankyo Co Ltd
- 7.13 Debiopharm International SA
- 7.14 Editas Medicine Inc
- 7.15 Eloxx Pharmaceuticals Inc
- 7.16 F. Hoffmann-La Roche Ltd
- 7.17 FibroGen Inc
- 7.18 Fulcrum Therapeutics Inc
- 7.19 Galapagos NV
- 7.20 Genethon SA
- 7.21 GTx Inc
- 7.22 Santhera Pharmaceuticals Holding AG
- 7.23 Sarepta Therapeutics Inc
- 7.24 SOM Biotech SL
- 7.25 Strykagen Corp
- 7.26 Summit Therapeutics Plc
- 7.27 Taiho Pharmaceutical Co Ltd
- 7.28 Teijin Pharma Ltd
- 7.29 WAVE Life Sciences Ltd
8 Duchenne Muscular Dystrophy Drugs Manufacturing Cost Analysis
- 8.1 Duchenne Muscular Dystrophy Drugs Key Raw Materials Analysis
- 8.1.1 Key Raw Materials
- 8.1.2 Price Trend of Key Raw Materials
- 8.1.3 Key Suppliers of Raw Materials
- 8.2 Proportion of Manufacturing Cost Structure
- 8.3 Manufacturing Process Analysis of Duchenne Muscular Dystrophy Drugs
- 8.4 Duchenne Muscular Dystrophy Drugs Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
- 9.1 Marketing Channel
- 9.1.1 Direct Marketing
- 9.1.2 Indirect Marketing
- 9.2 Duchenne Muscular Dystrophy Drugs Distributors List
- 9.3 Duchenne Muscular Dystrophy Drugs Customers
10 Market Dynamics
- 10.1 Market Trends
- 10.2 Opportunities
- 10.3 Market Drivers
- 10.4 Challenges
- 10.5 Influence Factors
11 Global Duchenne Muscular Dystrophy Drugs Market Forecast
- 11.1 Global Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast
- 11.1.1 Global Duchenne Muscular Dystrophy Drugs Production Growth Rate Forecast (2019-2025)
- 11.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate Forecast (2019-2025)
- 11.1.3 Global Duchenne Muscular Dystrophy Drugs Price and Trend Forecast (2019-2025)
- 11.2 Global Duchenne Muscular Dystrophy Drugs Production Forecast by Regions (2019-2025)
- 11.2.1 North America Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2019-2025)
- 11.2.2 Europe Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2019-2025)
- 11.2.3 China Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2019-2025)
- 11.2.4 Japan Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2019-2025)
- 11.3 Global Duchenne Muscular Dystrophy Drugs Consumption Forecast by Regions (2019-2025)
- 11.3.1 North America Duchenne Muscular Dystrophy Drugs Consumption Forecast (2019-2025)
- 11.3.2 Europe Duchenne Muscular Dystrophy Drugs Consumption Forecast (2019-2025)
- 11.3.3 China Duchenne Muscular Dystrophy Drugs Consumption Forecast (2019-2025)
- 11.3.4 Japan Duchenne Muscular Dystrophy Drugs Consumption Forecast (2019-2025)
- 11.4 Global Duchenne Muscular Dystrophy Drugs Production, Revenue and Price Forecast by Type (2019-2025)
- 11.5 Global Duchenne Muscular Dystrophy Drugs Consumption Forecast by Application (2019-2025)
12 Research Findings and Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Duchenne Muscular Dystrophy Drugs. Industry analysis & Market Report on Duchenne Muscular Dystrophy Drugs is a syndicated market report, published as Global Duchenne Muscular Dystrophy Drugs Market Research Report 2019. It is complete Research Study and Industry Analysis of Duchenne Muscular Dystrophy Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
